Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05757570 · ClinicalTrials.gov registry record · Phase 1
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
A Phase 1 study of Immune Thrombocytopenia and Cold Agglutinin Disease, sponsored by Alpine Immune Sciences.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 20
- Study locations
NCT05757570 is a Phase 1 study of Immune Thrombocytopenia and Cold Agglutinin Disease that is active but no longer recruiting, run by Alpine Immune Sciences. The registered enrollment target is 30 participants, below the 119-participant average among 6 other Immune Thrombocytopenia trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT05757570, a Phase 1 study of Immune Thrombocytopenia and Cold Agglutinin Disease, is active but no longer recruiting, sponsored by Alpine Immune Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to evaluate povetacicept in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month study treatment extension period.
Conditions Studied
Interventions
- DRUG povetacicept
Study Locations (20)
New York
- Investigational site (405) - Lake Success
- Investigational Site (423) - New Hyde Park
- Investigational Site (421) - New York
- Investigational Site (404) - New York
- Investigational Site (420) - Shirley
- Investigational Site (422) - The Bronx
Other
- Investigational Site (410) - Box Hill
- Investigational Site (519) - Concord
- Investigational Site (517) - Douglas
- Investigational Site (413) - Liverpool
- Investigational Site (407) - West Perth
Florida
- Investigational Site (419) - Cooper City
- Investigational Site (425) - Miami
North Carolina
- Investigational Site (414) - Charlotte
- Investigational Site (402) - Greenville
California
- Investigational Site (230) - Los Angeles
District of Columbia
- Investigational Site (401) - Washington D.C.
Iowa
- Investigational Site (219) - Iowa City
Maryland
- Investigational Site (435) - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-07-03 |
| Est. Completion | 2026-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05757570
The ClinicalTrials.gov registry entry for NCT05757570 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 119-participant average among 6 other Immune Thrombocytopenia trials with a reported enrollment target (75% lower). The listed sponsor is Alpine Immune Sciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Immune Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which povetacicept is the first listed.
NCT05757570 reports 20 study locations spanning 9 distinct geographic areas - top geographies include New York, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT05757570 about?
NCT05757570 is a clinical study titled "An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias". The goal of this clinical study is to evaluate povetacicept in adults with autoimmune cytopenias of immune thrombocytopenia, autoimmune hemolytic anemia, and cold agglutinin disease to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment...
What is the current status of trial NCT05757570?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-07-03. Estimated completion is 2026-07.
What conditions does trial NCT05757570 study?
This clinical trial studies the following conditions: Immune Thrombocytopenia, Cold Agglutinin Disease, Idiopathic Thrombocytopenic Purpura, Warm Autoimmune Hemolytic Anemia.
What interventions are being tested in trial NCT05757570?
The interventions under investigation include: povetacicept (DRUG).
Who is sponsoring clinical trial NCT05757570?
This trial is sponsored by Alpine Immune Sciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05757570 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Iowa, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
RECRUITING · Phase 2
-
Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
RECRUITING
-
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
RECRUITING · Phase 3
-
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
COMPLETED · Phase 4
-
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.